share_log

Pharmaxis Ltd: First patient dosed in Phase 2 trial of sleep disorder

Nov 9, 2023 06:28
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.